{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:27:47Z","timestamp":1790389667222,"version":"4.1.0"},"reference-count":189,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02052","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T04:55:06Z","timestamp":1536641706000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road"],"prefix":"10.3389","volume":"9","author":[{"given":"Cleo","family":"Goyvaerts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Breckpot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,9,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1084\/jem.137.5.1142","article-title":"Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution","volume":"137","author":"Steinman","year":"1973","journal-title":"J Exp Med."},{"key":"B2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1084\/jem.139.2.380","article-title":"Identification of a novel cell type in peripheral lymphoid organs of mice. II. Functional properties in vitro","volume":"139","author":"Steinman","year":"1974","journal-title":"J Exp Med."},{"key":"B3","unstructured":"Ralph M. Steinman - FactsNobelprize.org2011"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/imm.12888","article-title":"Human dendritic cell subsets: an update","volume":"154","author":"Collin","year":"2018","journal-title":"Immunology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/ni.2370","article-title":"Deciphering the transcriptional network of the dendritic cell lineage","volume":"13","author":"Miller","year":"2012","journal-title":"Nat Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3389\/fimmu.2015.00330","article-title":"Human and mouse mononuclear phagocyte networks: a tale of two species?","volume":"6","author":"Reynolds","year":"2015","journal-title":"Front Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.it.2013.06.001","article-title":"Inflammatory dendritic cells in mice and humans","volume":"34","author":"Segura","year":"2013","journal-title":"Trends Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"eaah4573","DOI":"10.1126\/science.aah4573","article-title":"Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors","volume":"356","author":"Villani","year":"2017","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.it.2017.06.008","article-title":"Langerhans cells - The macrophage in dendritic cell clothing","volume":"38","author":"Doebel","year":"2017","journal-title":"Trends Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s13238-012-2104-8","article-title":"Regulation of TLR7\/9 signaling in plasmacytoid dendritic cells","volume":"4","author":"Bao","year":"2013","journal-title":"Protein Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1084\/jem.20092618","article-title":"Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells","volume":"207","author":"Poulin","year":"2010","journal-title":"J Exp Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1084\/jem.20100348","article-title":"Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells","volume":"207","author":"Bachem","year":"2010","journal-title":"J Exp Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.immuni.2012.04.012","article-title":"Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells","volume":"37","author":"Haniffa","year":"2012","journal-title":"Immunity"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1084\/jem.20092140","article-title":"Human CD141 + (BDCA-3) + dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens","volume":"207","author":"Jongbloed","year":"2010","journal-title":"J Exp Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1189\/jlb.0912452","article-title":"Human blood mDC subsets exhibit distinct TLR repertoire and responsiveness","volume":"93","author":"H\u00e9mont","year":"2013","journal-title":"J Leukoc Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.ai.2015.03.002","article-title":"Cross-presentation in mouse and human dendritic cells","volume":"127","author":"Segura","year":"","journal-title":"Adv Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/OAJU.S13069","article-title":"Sipuleucel-T: immunotherapy for advanced prostate cancer","volume":"3","author":"Olson","year":"2011","journal-title":"Open Access J Urol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","article-title":"Clinical use of dendritic cells for cancer therapy","volume":"15","author":"Anguille","year":"2014","journal-title":"Lancet Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e23431","DOI":"10.4161\/onci.23431","article-title":"Naturally circulating dendritic cells to vaccinate cancer patients","volume":"2","author":"Bol","year":"2013","journal-title":"Oncoimmunology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1158\/1078-0432.CCR-15-1399","article-title":"Dendritic cell-based immunotherapy: state of the art and beyond","volume":"22","author":"Bol","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1158\/0008-5472.CAN-12-2583","article-title":"Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients","volume":"73","author":"Tel","year":"2013","journal-title":"Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3389\/fimmu.2014.00165","article-title":"Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets","volume":"5","author":"Wimmers","year":"2014","journal-title":"Front Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3389\/fimmu.2013.00053","article-title":"The nature of activatory and tolerogenic dendritic cell-derived signal II","volume":"4","author":"Bakdash","year":"2013","journal-title":"Front Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"785634","DOI":"10.1155\/2015\/785634","article-title":"Pros and cons of antigen-presenting cell targeted tumor vaccines","volume":"2015","author":"Goyvaerts","year":"2015","journal-title":"J Immunol Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"704","DOI":"10.18632\/oncotarget.1680","article-title":"Immunogenicity of targeted lentivectors","volume":"5","author":"Goyvaerts","year":"2014","journal-title":"Oncotarget"},{"key":"B26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.immuni.2017.01.003","article-title":"CD8 + T cells orchestrate pDC-XCR1 + dendritic cell spatial and functional cooperativity to optimize priming","volume":"46","author":"Brewitz","year":"2017","journal-title":"Immunity"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s00262-007-0334-z","article-title":"Current approaches in dendritic cell generation and future implications for cancer immunotherapy","volume":"56","author":"Tuyaerts","year":"2007","journal-title":"Cancer Immunol Immunother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/jgm.615","article-title":"Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells","volume":"6","author":"Breckpot","year":"2004","journal-title":"J Gene Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2174\/156652305774964758","article-title":"Genetically modified dendritic cells for cancer immunotherapy","volume":"5","author":"Ribas","year":"2005","journal-title":"Curr Gene Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"565643","DOI":"10.1155\/2010\/565643","article-title":"Gene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy","volume":"2010","author":"Chen","year":"2010","journal-title":"Clin Dev Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.nantod.2014.10.001","article-title":"Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment","volume":"9","author":"Dewitte","year":"2014","journal-title":"Nano Today"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e326","DOI":"10.1038\/mtna.2016.38","article-title":"Particle-mediated intravenous delivery of antigen mRNA results in strong antigen-specific T-cell responses despite the induction of type I interferon","volume":"5","author":"Broos","year":"2016","journal-title":"Mol Ther Nucleic Acids"},{"key":"B33","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1586\/14760584.2015.957685","article-title":"The ReNAissanCe of mRNA-based cancer therapy","volume":"14","author":"Van","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"B34","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/nri3727","article-title":"Dendritic cell-targeted vaccines - hope or hype?","volume":"14","author":"Kastenm\u00fcller","year":"2014","journal-title":"Nat Rev Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1182\/blood-2004-10-3880","article-title":"Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy","volume":"105","author":"Tan","year":"2005","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"5627","DOI":"10.1128\/JVI.00014-10","article-title":"HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7","volume":"84","author":"Breckpot","year":"2010","journal-title":"J Virol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/diseases6020042","article-title":"Viral vectors in gene therapy","volume":"6","author":"Lundstrom","year":"2018","journal-title":"Diseases"},{"key":"B38","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/sj.gt.3302697","article-title":"Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors","volume":"13","author":"Dullaers","year":"2006","journal-title":"Gene Ther."},{"key":"B39","first-page":"676","article-title":"Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus","volume":"59","author":"Kass","year":"1999","journal-title":"Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/PPO.0b013e3182325e63","article-title":"Viral vector-based therapeutic cancer vaccines","volume":"17","author":"Larocca","year":"2011","journal-title":"Cancer J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.molmed.2012.07.007","article-title":"Recombinant viral vaccines for cancer","volume":"18","author":"Cawood","year":"2012","journal-title":"Trends Mol Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00262-017-2025-8","article-title":"Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer","volume":"66","author":"Hamid","year":"2017","journal-title":"Cancer Immunol Immunother."},{"key":"B43","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/14712598.2017.1338684","article-title":"Viral gene therapy for breast cancer: progress and challenges","volume":"17","author":"Asad","year":"2017","journal-title":"Expert Opin Biol Ther."},{"key":"B44","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/jnci\/87.13.982","article-title":"Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine","volume":"87","author":"Tsang","year":"1995","journal-title":"J Natl Cancer Inst."},{"key":"B45","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/pros.10130","article-title":"Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer","volume":"53","author":"Gulley","year":"2002","journal-title":"Prostate"},{"key":"B46","first-page":"34","article-title":"Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine","volume":"6","author":"Conry","year":"2000","journal-title":"Clin Cancer Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.1200\/JCO.2000.18.23.3964","article-title":"Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti\u2013carcinoembryonic antigen immune responses","volume":"18","author":"Marshall","year":"2000","journal-title":"J Clin Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"9654","DOI":"10.1128\/JVI.75.20.9654-9664.2001","article-title":"Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site","volume":"75","author":"Lamikanra","year":"2001","journal-title":"J Virol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s002620000146","article-title":"Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule","volume":"49","author":"H\u00f6rig","year":"2000","journal-title":"Cancer Immunol Immunother."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00262-005-0096-4","article-title":"Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated","volume":"55","author":"Harrop","year":"2006","journal-title":"Cancer Immunol Immunother."},{"key":"B51","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/imm.12884","article-title":"CD70 encoded by modified vaccinia virus Ankara enhances CD8 T-cell-dependent protective immunity in MHC class II-deficient mice","volume":"154","author":"Bathke","year":"2018","journal-title":"Immunology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"73469","DOI":"10.18632\/oncotarget.20703","article-title":"Enhanced immunotherapy by combining a vaccine with a novel murine GITR ligand fusion protein","volume":"8","author":"Morillon","year":"2017","journal-title":"Oncotarget"},{"key":"B53","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00262-010-0935-9","article-title":"A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings","volume":"60","author":"Oudard","year":"2011","journal-title":"Cancer Immunol Immunother."},{"key":"B54","first-page":"5800","article-title":"A triad of costimulatory molecules synergize to amplify T-cell activation","volume":"59","author":"Hodge","year":"1999","journal-title":"Cancer Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1158\/1078-0432.CCR-08-0126","article-title":"Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma","volume":"14","author":"Gulley","year":"2008","journal-title":"Clin Cancer Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"7164","DOI":"10.1158\/1078-0432.CCR-11-0649","article-title":"A pilot study of MUC-1\/CEA\/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer","volume":"17","author":"Mohebtash","year":"2011","journal-title":"Clin Cancer Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1089\/hum.2006.17.239","article-title":"Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors","volume":"17","author":"Kaufman","year":"2006","journal-title":"Hum Gene Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00262-013-1448-0","article-title":"Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer","volume":"62","author":"Gulley","year":"2013","journal-title":"Cancer Immunol Immunother."},{"key":"B59","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1158\/1078-0432.CCR-04-2283","article-title":"Phase I Study of the intratumoral administration of recombinant canarypox viruses expressing B7. 1 and interleukin 12 in patients with metastatic melanoma","volume":"11","author":"Triozzi","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"Kantoff","year":"2010","journal-title":"J Clin Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00262-009-0782-8","article-title":"Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer","volume":"59","author":"Gulley","year":"2010","journal-title":"Cancer Immunol Immunother."},{"key":"B62","first-page":"1181","article-title":"The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma","volume":"7","author":"von","year":"2001","journal-title":"Clin Cancer Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-10-2082","article-title":"Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study","volume":"16","author":"Amato","year":"2010","journal-title":"Clin Cancer Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/S1470-2045(11)70259-5","article-title":"Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial","volume":"12","author":"Quoix","year":"2011","journal-title":"Lancet Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40425-017-0274-x","article-title":"Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC","volume":"5","author":"Tosch","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B66","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/978-1-4615-0685-0_61","article-title":"Clinical studies of human papilloma vaccines in cervical cancer","volume":"495","author":"Adams","year":"2001","journal-title":"Adv Exp Med Biol."},{"key":"B67","first-page":"3676","article-title":"Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer","volume":"8","author":"Kaufmann","year":"2002","journal-title":"Clin Cancer Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1586\/erv.13.23","article-title":"Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer","volume":"12","author":"Morrow","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"B69","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S1470-2045(12)70006-2","article-title":"Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial","volume":"13","author":"Madan","year":"2012","journal-title":"Lancet Oncol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1128\/JVI.02386-13","article-title":"The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys","volume":"88","author":"Teigler","year":"2014","journal-title":"J Virol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/CJI.0b013e3182941813","article-title":"Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4","volume":"36","author":"Hanwell","year":"2013","journal-title":"J Immunother."},{"key":"B72","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1158\/1078-0432.CCR-05-2732","article-title":"Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I\/II trial","volume":"12","author":"Harrop","year":"2006","journal-title":"Clin Cancer Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","article-title":"Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine","volume":"4","author":"Lee","year":"2017","journal-title":"Genes Dis"},{"key":"B74","doi-asserted-by":"publisher","first-page":"7881","DOI":"10.1016\/j.vaccine.2010.09.079","article-title":"Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans","volume":"28","author":"Bett","year":"2010","journal-title":"Vaccine"},{"key":"B75","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/415331a","article-title":"Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity","volume":"415","author":"Shiver","year":"2002","journal-title":"Nature"},{"key":"B76","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/01.cji.0000211312.36363.56","article-title":"Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors","volume":"29","author":"Lotem","year":"2006","journal-title":"J Immunother."},{"key":"B77","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/sj.gt.3301880","article-title":"Priming of T cells with Ad-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8+ T cells: implications for an efficient vaccination strategy","volume":"10","author":"Tuettenberg","year":"2003","journal-title":"Gene Ther."},{"key":"B78","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<89::AID-IJC14>3.0.CO;2-I","article-title":"Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma","volume":"86","author":"Steitz","year":"2000","journal-title":"Int J Cancer"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/j.vaccine.2011.01.022","article-title":"Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine","volume":"29","author":"Hangalapura","year":"2011","journal-title":"Vaccine"},{"key":"B80","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.1158\/0008-5472.CAN-11-0804","article-title":"Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine","volume":"71","author":"Hangalapura","year":"2011","journal-title":"Cancer Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00262-006-0247-2","article-title":"Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice","volume":"56","author":"Gomez-Gutierrez","year":"2007","journal-title":"Cancer Immunol Immunother."},{"key":"B82","doi-asserted-by":"publisher","first-page":"12807","DOI":"10.1128\/JVI.79.20.12807-12817.2005","article-title":"Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses","volume":"79","author":"B\u00e1ez-Ast\u00faa","year":"2005","journal-title":"J Virol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/mt.2009.130","article-title":"New insights on adenovirus as vaccine vectors","volume":"17","author":"Lasaro","year":"2009","journal-title":"Mol Ther."},{"key":"B84","doi-asserted-by":"publisher","first-page":"7375","DOI":"10.1158\/1078-0432.CCR-09-1910","article-title":"Phase I clinical trial of an adenovirus\/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results","volume":"15","author":"Lubaroff","year":"2009","journal-title":"Clin Cancer Res."},{"key":"B85","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1200\/JCO.2017.72.3064","article-title":"Intravesical rAd\u2013IFN\u03b1\/Syn3 for patients with high-grade, bacillus calmette-guerin\u2013refractory or relapsed non\u2013muscle-invasive bladder cancer: a phase II randomized study","volume":"35","author":"Shore","year":"2017","journal-title":"J Clin Oncol."},{"key":"B86","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/jnci\/90.24.1894","article-title":"Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens","volume":"90","author":"Rosenberg","year":"1998","journal-title":"J Natl Cancer Inst."},{"key":"B87","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1159\/000020281","article-title":"Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I\/II clinical trial","volume":"38","author":"Mincheff","year":"2000","journal-title":"Eur Urol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.ymthe.2006.01.013","article-title":"Phase I trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer","volume":"13","author":"Nemunaitis","year":"2006","journal-title":"Mol Ther."},{"key":"B89","first-page":"1399","article-title":"New approaches to the development of adenoviral dendritic cell vaccines in melanoma","volume":"11","author":"Butterfield","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"B90","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1001\/archderm.138.6.799","article-title":"Hypopigmentation associated with an adenovirus-mediated gp100\/MART-1\u2013transduced dendritic cell vaccine for metastatic melanoma","volume":"138","author":"Tsao","year":"2002","journal-title":"Arch Dermatol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/CJI.0b013e31816a8910","article-title":"Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma","volume":"31","author":"Butterfield","year":"2008","journal-title":"J Immunother."},{"key":"B92","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1517\/14712598.2010.484801","article-title":"INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect","volume":"10","author":"Chiappori","year":"2010","journal-title":"Expert Opin Biol Ther."},{"key":"B93","doi-asserted-by":"publisher","first-page":"e98368","DOI":"10.1172\/jci.insight.98368","article-title":"Efficacy of intracellular immune checkpoint-silenced DC vaccine","volume":"3","author":"Wang","year":"2018","journal-title":"JCI Insight"},{"key":"B94","doi-asserted-by":"crossref","first-page":"143","DOI":"10.5772\/61844","article-title":"Chapter 5: Retroviral vectors in gene therapy","volume-title":"Advances in Molecular Retrovirology","author":"Matuskova","year":"2016"},{"key":"B95","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/1742-4690-9-105","article-title":"SAMHD1 restricts HIV-1 infection in dendritic cells (DCs) by dNTP depletion, but its expression in DCs and primary CD4+ T-lymphocytes cannot be upregulated by interferons","volume":"9","author":"St","year":"2012","journal-title":"Retrovirology"},{"key":"B96","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.virol.2012.11.010","article-title":"Intracellular nucleotide levels and the control of retroviral infections","volume":"436","author":"Amie","year":"2013","journal-title":"Virology"},{"key":"B97","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2174\/1566524011313040011","article-title":"Lentiviral vectors: a versatile tool to fight cancer","volume":"13","author":"Emeagi","year":"2013","journal-title":"Curr Mol Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.1038\/nature05219","article-title":"X-SCID transgene leukaemogenicity","volume":"443","author":"Thrasher","year":"2006","journal-title":"Nature"},{"key":"B99","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1056\/NEJM200301163480314","article-title":"A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency","volume":"348","author":"Hacein-Bey-Abina","year":"2003","journal-title":"N Engl J Med."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1182\/blood-2007-01-068759","article-title":"Hot spots of retroviral integration in human CD34+ hematopoietic cells","volume":"110","author":"Cattoglio","year":"2007","journal-title":"Blood"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1016\/j.ymthe.2017.04.028","article-title":"Eliminating HIV-1 packaging sequences from lentiviral vector proviruses enhances safety and expedites gene transfer for gene therapy","volume":"25","author":"Vink","year":"2017","journal-title":"Mol Ther."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/gt.2011.206","article-title":"Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells","volume":"19","author":"Goyvaerts","year":"2012","journal-title":"Gene Ther."},{"key":"B103","doi-asserted-by":"publisher","first-page":"11304","DOI":"10.1128\/JVI.01498-13","article-title":"Targeting of human antigen-presenting cell subsets","volume":"87","author":"Goyvaerts","year":"2013","journal-title":"J Virol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00005-010-0063-4","article-title":"Lentiviral vectors in gene therapy: their current status and future potential","volume":"58","author":"Escors","year":"2010","journal-title":"Arch Immunol Ther Exp."},{"key":"B105","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1600-065X.2010.00967.x","article-title":"Immunization delivered by lentiviral vectors for cancer and infectious diseases","volume":"239","author":"Hu","year":"2011","journal-title":"Immunol Rev."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1089\/hum.2005.16.1255","article-title":"Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine","volume":"16","author":"Kim","year":"2005","journal-title":"Hum Gene Ther."},{"key":"B107","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/nbt1216","article-title":"Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration","volume":"24","author":"Montini","year":"2006","journal-title":"Nat Biotechnol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"16010","DOI":"10.1038\/mto.2016.10","article-title":"LV305, a dendritic cell-targeting integration-deficient ZVex(TM)-based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response","volume":"3","author":"Albershardt","year":"2016","journal-title":"Mol Ther oncolytics"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0000000000000183","article-title":"First-in-human treatment with a dendritic cell-targeting lentiviral vector-expressing NY-ESO-1, LV305, induces deep, durable response in refractory metastatic synovial sarcoma patient","volume":"40","author":"Pollack","year":"2017","journal-title":"J Immunother."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14760584.2018.1419068","article-title":"The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid\/round cell liposarcoma patients","volume":"17","author":"Pollack","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"B111","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/v1010013","article-title":"Alphaviruses in gene therapy","volume":"1","author":"Lundstrom","year":"2009","journal-title":"Viruses"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1002\/0471142301.ns0422s57","article-title":"Alphaviruses: semliki forest virus and sindbis virus vectors for gene transfer into neurons","volume":"57","author":"Ehrengruber","year":"2011","journal-title":"Curr Protoc Neurosci."},{"key":"B113","doi-asserted-by":"publisher","first-page":"4906","DOI":"10.2174\/1381612823666170622094715","article-title":"Application of alphaviral vectors for immunomodulation in cancer therapy","volume":"23","author":"Zajakina","year":"2017","journal-title":"Curr Pharm Des."},{"key":"B114","doi-asserted-by":"publisher","first-page":"11849","DOI":"10.1128\/JVI.74.24.11849-11857.2000","article-title":"Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein","volume":"74","author":"Gardner","year":"2000","journal-title":"J Virol."},{"key":"B115","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/135965350400900515","article-title":"Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization","volume":"9","author":"Daemen","year":"2004","journal-title":"Antivir Ther."},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1029699","article-title":"A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development","author":"Draghiciu","year":"2015","journal-title":"Oncoimmunology"},{"key":"B117","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF02700029","article-title":"Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene\u2013a phase I\/II clinical protocol","volume":"64","author":"Ren","year":"2003","journal-title":"J Neurooncol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1186\/bcr3204","article-title":"Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells","volume":"14","author":"Ren","year":"2012","journal-title":"Breast Cancer Res."},{"key":"B119","doi-asserted-by":"publisher","first-page":"R145","DOI":"10.1186\/bcr962","article-title":"Alphavirus replicon particles containing the gene for HER2\/neu inhibit breast cancer growth and tumorigenesis","volume":"7","author":"Wang","year":"2005","journal-title":"Breast Cancer Res."},{"key":"B120","doi-asserted-by":"publisher","first-page":"6604","DOI":"10.1016\/j.vaccine.2007.06.058","article-title":"Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice","volume":"25","author":"Moran","year":"2007","journal-title":"Vaccine"},{"key":"B121","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3389\/fendo.2017.00270","article-title":"Breast cancer vaccines: new insights","volume":"8","author":"Benedetti","year":"2017","journal-title":"Front Endocrinol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"P444","DOI":"10.1186\/2051-1426-3-S2-P444","article-title":"Phase I study of alphaviral vector (AVX701) in colorectal cancer patients: comparison of immune responses in stage III and stage IV patients","volume":"3","author":"Morse","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B123","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1172\/JCI42672","article-title":"An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer","volume":"120","author":"Morse","year":"2010","journal-title":"J Clin Invest."},{"key":"B124","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/vaccines5020009","article-title":"Oncolytic alphaviruses in cancer immunotherapy","volume":"5","author":"Lundstrom","year":"2017","journal-title":"Vaccines"},{"key":"B125","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/biomedicines5010008","article-title":"Oncolytic vesicular stomatitis virus as a viro-immunotherapy: defeating cancer with a \u201cHammer\u201d and \u201cAnvil\u201d","volume":"5","author":"Melzer","year":"2017","journal-title":"Biomedicines"},{"key":"B126","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/mt.2013.249","article-title":"Maraba virus as a potent oncolytic vaccine vector","volume":"22","author":"Pol","year":"2014","journal-title":"Mol Ther."},{"key":"B127","unstructured":"73947P T412016"},{"key":"B128","unstructured":"194246P T432018"},{"key":"B129","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.bbrep.2017.12.004","article-title":"Measles virus: background and oncolytic virotherapy","volume":"13","author":"Bhattacharjee","year":"2018","journal-title":"Biochem Biophys Rep."},{"key":"B130","first-page":"43","article-title":"Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview","volume":"11","author":"Msaouel","year":"2009","journal-title":"Curr Opin Mol Ther."},{"key":"B131","first-page":"2462","article-title":"Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme","volume":"63","author":"Phuong","year":"2003","journal-title":"Cancer Res."},{"key":"B132","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/1521-4141(200201)32:1<30::AID-IMMU30>3.0.CO;2-E","article-title":"Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus\/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells","volume":"32","author":"Chiriva-Internati","year":"2002","journal-title":"Eur J Immunol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/sj.cgt.7700391","article-title":"Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector","volume":"8","author":"Liu","year":"2001","journal-title":"Cancer Gene Ther."},{"key":"B134","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1479-5876-6-56","article-title":"Protective CD8+ T-cell responses to cytomegalovirus driven by rAAV\/GFP\/IE1 loading of dendritic cells","volume":"6","author":"Yu","year":"2008","journal-title":"J Transl Med."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00262-007-0307-2","article-title":"Generation of robust cytotoxic T lymphocytes against prostate specific antigen by transduction of dendritic cells using protein and recombinant adeno-associated virus","volume":"56","author":"Mahadevan","year":"2007","journal-title":"Cancer Immunol Immunother."},{"key":"B136","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1089\/vim.2008.0029","article-title":"rAAV\/Her-2\/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer","volume":"21","author":"Yu","year":"2008","journal-title":"Viral Immunol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/sj.cgt.7700785","article-title":"Use and specificity of breast cancer antigen\/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells","volume":"12","author":"Liu","year":"2005","journal-title":"Cancer Gene Ther."},{"key":"B138","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/ijc.20530","article-title":"Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody","volume":"113","author":"Liu","year":"2005","journal-title":"Int J Cancer"},{"key":"B139","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/icb.2013.74","article-title":"Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy","volume":"92","author":"Pandya","year":"2013","journal-title":"Immunol Cell Biol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jconrel.2016.01.001","article-title":"Adeno-associated virus (AAV) vectors in cancer gene therapy","volume":"240","author":"Santiago-Ortiz","year":"2016","journal-title":"J Control Release"},{"key":"B141","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/MT.2008.76","article-title":"Analysis of AAV Serotypes 1\u20139 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol Ther."},{"key":"B142","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/hgtb.2012.243","article-title":"Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy","volume":"24","author":"Louis","year":"2013","journal-title":"Hum Gene Ther Methods"},{"key":"B143","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/CJI.0000000000000093","article-title":"Reprogramming immune response with capsid-optimized AAV6 vectors for immunotherapy of cancer","volume":"38","author":"Pandya","year":"2015","journal-title":"J Immunother."},{"key":"B144","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3390\/v4061011","article-title":"Mechanisms of coronavirus cell entry mediated by the viral spike protein","volume":"4","author":"Belouzard","year":"2012","journal-title":"Viruses"},{"key":"B145","doi-asserted-by":"publisher","first-page":"e00171","DOI":"10.1128\/mBio.00171-10","article-title":"Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity","volume":"1","author":"Cervantes-Barragan","year":"2010","journal-title":"MBio"},{"key":"B146","doi-asserted-by":"publisher","first-page":"e81442","DOI":"10.1371\/journal.pone.0081442","article-title":"Dendritic cell-specific delivery of Flt3L by coronavirus vectors secures induction of therapeutic antitumor immunity","volume":"8","author":"Perez-Shibayama","year":"2013","journal-title":"PLoS ONE"},{"key":"B147","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S1470-2045(14)71179-9","article-title":"Next generation prophylactic human papillomavirus vaccines","volume":"16","author":"Schiller","year":"2015","journal-title":"Lancet Oncol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S0929-6646(10)60017-4","article-title":"Perspectives for preventive and therapeutic HPV vaccines","volume":"109","author":"Lin","year":"2010","journal-title":"J Formos Med Assoc."},{"key":"B149","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1172\/JCI63287","article-title":"Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses","volume":"122","author":"\u00c7uburu","year":"2012","journal-title":"J Clin Invest."},{"key":"B150","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.omtm.2017.04.005","article-title":"Efficient production of papillomavirus gene delivery vectors in defined in vitro reactions","volume":"5","author":"Cerqueira","year":"2017","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B151","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/ps.393","article-title":"Recombinant baculoviruses for insect control","volume":"57","author":"Inceoglu","year":"2001","journal-title":"Pest Manag Sci."},{"key":"B152","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/nbt1095","article-title":"Baculovirus as versatile vectors for protein expression in insect and mammalian cells","volume":"23","author":"Kost","year":"2005","journal-title":"Nat Biotechnol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.vaccine.2008.10.055","article-title":"Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells","volume":"27","author":"Betting","year":"2009","journal-title":"Vaccine"},{"key":"B154","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/cmi.2010.48","article-title":"Induction of antitumor immunity against mouse carcinoma by baculovirus-infected dendritic cells","volume":"7","author":"Suzuki","year":"2010","journal-title":"Cell Mol Immunol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cellimm.2009.12.005","article-title":"Baculovirus activates murine dendritic cells and induces non-specific NK cell and T cell immune responses","volume":"262","author":"Suzuki","year":"2010","journal-title":"Cell Immunol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3892\/ijo.2013.2125","article-title":"Intradermal immunization with combined baculovirus and tumor cell lysate induces effective antitumor immunity in mice","volume":"43","author":"Kawahara","year":"2013","journal-title":"Int J Oncol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"8663","DOI":"10.1128\/JVI.78.16.8663-8672.2004","article-title":"Baculovirus vectors elicit antigen-specific immune responses in mice","volume":"78","author":"Facciabene","year":"2004","journal-title":"J Virol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.1016\/j.jip.2011.05.010","article-title":"Requirements for baculoviruses for clinical gene therapy applications","volume":"107","author":"Lesch","year":"2011","journal-title":"J Invertebr Pathol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/mt.2009.275","article-title":"Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma","volume":"18","author":"Adamina","year":"2010","journal-title":"Mol Ther."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1089\/104303403322495016","article-title":"Phase I\/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients","volume":"14","author":"Zajac","year":"2003","journal-title":"Hum Gene Ther."},{"key":"B161","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1158\/0008-5472.CAN-11-2957","article-title":"Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy","volume":"72","author":"Van","year":"2012","journal-title":"Cancer Res."},{"key":"B162","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jconrel.2017.09.041","article-title":"Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: restoring the immunogenicity of immunosilent mRNA","volume":"266","author":"Verbeke","year":"2017","journal-title":"J Control Release"},{"key":"B163","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1182\/blood-2006-10-049312","article-title":"In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance","volume":"109","author":"Brown","year":"2007","journal-title":"Blood"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1099\/mic.0.049601-0","article-title":"Pre-existing immunity against vaccine vectors\u2013friend or foe?","volume":"159","author":"Saxena","year":"2013","journal-title":"Microbiology"},{"key":"B165","doi-asserted-by":"publisher","first-page":"5567","DOI":"10.1128\/JVI.00405-09","article-title":"Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo","volume":"83","author":"Pichla-Gollon","year":"2009","journal-title":"J Virol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.immuni.2010.10.004","article-title":"Immunologic basis of vaccine vectors","volume":"33","author":"Liu","year":"2010","journal-title":"Immunity"},{"key":"B167","doi-asserted-by":"publisher","first-page":"e18526","DOI":"10.1371\/journal.pone.0018526","article-title":"Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5\/HIV-1 vaccine candidate in humans","volume":"6","author":"Pine","year":"2011","journal-title":"PLoS ONE"},{"key":"B168","doi-asserted-by":"publisher","first-page":"5691","DOI":"10.1016\/j.vaccine.2010.06.050","article-title":"Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28","volume":"28","author":"Kahl","year":"2010","journal-title":"Vaccine"},{"key":"B169","doi-asserted-by":"publisher","first-page":"4844","DOI":"10.1128\/JVI.02616-07","article-title":"Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys","volume":"82","author":"Liu","year":"2008","journal-title":"J Virol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"001","DOI":"10.4172\/2155-9899.S4-001","article-title":"New recombinant Ad5 vector overcomes Ad5 immunity allowing for multiple safe, homologous immunizations","author":"Gabitzsch","year":"2012","journal-title":"J Clin Cell Immunol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature04721","article-title":"Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity","volume":"441","author":"Roberts","year":"2006","journal-title":"Nature"},{"key":"B172","doi-asserted-by":"publisher","first-page":"e34884","DOI":"10.1371\/journal.pone.0034884","article-title":"Pre-existing vector immunity does not prevent replication deficient adenovirus from inducing efficient CD8 T-cell memory and recall responses","volume":"7","author":"Steffensen","year":"2012","journal-title":"PLoS ONE"},{"key":"B173","doi-asserted-by":"publisher","first-page":"e31177","DOI":"10.1371\/journal.pone.0031177","article-title":"Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin","volume":"7","author":"Alexander","year":"2012","journal-title":"PLoS One"},{"key":"B174","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1073\/pnas.96.8.4512","article-title":"Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity","volume":"96","author":"Belyakov","year":"1999","journal-title":"Proc Natl Acad Sci USA."},{"key":"B175","doi-asserted-by":"publisher","first-page":"10780","DOI":"10.1128\/JVI.77.20.10780-10789.2003","article-title":"Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier","volume":"77","author":"Xiang","year":"2003","journal-title":"J Virol."},{"key":"B176","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/mt.2009.118","article-title":"Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer","volume":"17","author":"Chang","year":"2009","journal-title":"Mol Ther."},{"key":"B177","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1006\/mthe.2000.0045","article-title":"Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors","volume":"1","author":"Xiao","year":"2000","journal-title":"Mol Ther."},{"key":"B178","first-page":"3713","article-title":"Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases","volume":"6","author":"Worth","year":"2000","journal-title":"Clin Cancer Res."},{"key":"B179","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41417-017-0002-1","article-title":"Development of an adenovirus vector vaccine platform for targeting dendritic cells","volume":"25","author":"Sharma","year":"2018","journal-title":"Cancer Gene Ther."},{"key":"B180","doi-asserted-by":"publisher","first-page":"e101644","DOI":"10.1371\/journal.pone.0101644","article-title":"Immunization of mice with lentiviral vectors targeted to MHC class II+ cells is due to preferential transduction of dendritic cells in vivo","volume":"9","author":"Cir\u00e9","year":"2014","journal-title":"PLoS ONE"},{"key":"B181","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/gt.2017.30","article-title":"Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery","volume":"24","author":"Goyvaerts","year":"2017","journal-title":"Gene Ther."},{"key":"B182","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1128\/CVI.00286-10","article-title":"Translating tumor antigens into cancer vaccines","volume":"18","author":"Buonaguro","year":"2011","journal-title":"Clin Vaccine Immunol."},{"key":"B183","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40425-017-0270-1","article-title":"Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer","volume":"5","author":"Donaldson","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B184","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/mt.2015.115","article-title":"Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses","volume":"23","author":"Woller","year":"2015","journal-title":"Mol Ther."},{"key":"B185","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/21645515.2015.1094595","article-title":"Recombinant and epitope-based vaccines on the road to the market and implications for vaccine design and production","volume":"12","author":"Oyarz\u00fan","year":"2016","journal-title":"Hum Vaccin Immunother."},{"key":"B186","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.biomaterials.2014.10.050","article-title":"Nanovaccine loaded with poly I:C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo","volume":"38","author":"Luo","year":"2015","journal-title":"Biomaterials"},{"key":"B187","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/gt.2013.35","article-title":"Downregulation of Stat3 in melanoma: reprogramming the immune microenvironment as an anticancer therapeutic strategy","volume":"20","author":"Emeagi","year":"2013","journal-title":"Gene Ther."},{"key":"B188","doi-asserted-by":"publisher","first-page":"9044","DOI":"10.1128\/JVI.00844-15","article-title":"Lentiviral protein transfer vectors are an efficient vaccine platform and induce a strong antigen-specific cytotoxic T cell response","volume":"89","author":"Uhlig","year":"2015","journal-title":"J Virol."},{"key":"B189","doi-asserted-by":"publisher","first-page":"e1426519","DOI":"10.1080\/2162402X.2018.1426519","article-title":"M7824, a novel bifunctional anti-PD-L1\/TGF\u03b2 Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine","volume":"7","author":"Knudson","year":"2018","journal-title":"Oncoimmunology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02052\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T02:05:53Z","timestamp":1661997953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02052\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,11]]},"references-count":189,"alternative-id":["10.3389\/fimmu.2018.02052"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02052","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,11]]},"article-number":"2052"}}